East Region Formulary
NHS Scotland

Formulary Decisions

Search for the outcome of decisions made by the Formulary Committee

Filter
Select filter(s)
Baricitinib
Baricitinib
Routinely available
Local application
28/09/2022

Indication

For hospitalised patients with COVID-19 (Adults aged 18 and over) in line with local or regional guidance and coronavirus (COVID-19) alerts issued by the MHRA Central Alerting System. The most up to date national CMO guidance can be found here: https://www.cas.mhra.gov.uk/Help/CoronavirusAlerts.aspx...

For hospitalised patients with COVID-19 (Adults aged 18 and over) in line with local or regional guidance and coronavirus (COVID-19) alerts issued by the MHRA Central Alerting System. The most up to date national CMO guidance can be found here: https://www.cas.mhra.gov.uk/Help/CoronavirusAlerts.aspx.

Therapeutic Area

Infections

Status Description

Routinely available in line with local or regional guidance

Formulation

2mg and 4mg film-coated tablets

Comments

Prescribe as the Eli Lilly brand. Classified for use under policy for the use of unlicensed medicines. The ERFC approved formulary inclusion of Baricitinib in line with CMO guidance for adult patients only. For use in paediatrics discuss with paediatric specialists and follow local board non-formulary procedures.